US 12,465,251 B2
Analyte sensors featuring enhancements for decreasing interferent signal
Stephen Oja, Alameda, CA (US); Cade Brylee Fox, Burlingame, CA (US); Lam N. Tran, Dublin, CA (US); Zenghe Liu, Alameda, CA (US); Benjamin J. Feldman, Berkeley, CA (US); Udo Hoss, San Ramon, CA (US); Mark Stephen Yahnke, Alameda, CA (US); Tahir S. Khan, Fremont, CA (US); Jean-Pierre Babka, Alameda, CA (US); and Owen Daniel Reynolds, Cricklade (GB)
Assigned to ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed by ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed on Jun. 15, 2021, as Appl. No. 17/347,845.
Claims priority of provisional application 63/049,210, filed on Jul. 8, 2020.
Prior Publication US 2022/0007978 A1, Jan. 13, 2022
Int. Cl. A61B 5/1486 (2006.01); A61B 5/145 (2006.01)
CPC A61B 5/14865 (2013.01) [A61B 5/14532 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An in-vivo analyte sensor comprising:
a working electrode comprising an active area disposed thereon, the active area including an analyte-responsive enzyme;
a scrubbing electrode, wherein the scrubbing electrode is positioned in a facing relationship to the active area of the working electrode and the working electrode and scrubbing electrode are separated by a layer between the working electrode and the scrubbing electrode and configured to permit bodily fluids to pass between the working electrode and scrubbing electrode, wherein the scrubbing electrode has a width greater than the working electrode and wherein the scrubbing electrode is configured to reduce a signal attributed to an interferent of the working electrode by pre-reacting the interferent before the interferent reaches the working electrode; and
an additional electrode, wherein the additional electrode is at least one of a counter electrode or a reference electrode, wherein the in-vivo analyte sensor is configured for in-vivo use.